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HEROIN MAINTENANCE TREATMENT: ITS
EFFECTIVENESS AND THE LEGISLATIVE
CHANGES NECESSARY TO IMPLEMENT IT IN
THE U.S.
Jessica G. Katz*

I. INTRODUCTION

Heroin is the most rapidly acting and widely abused opiate.' According to
the 2008 National Survey on Drug Use and Health, approximately 3.8
million Americans over the age of twelve have tried heroin at least once in
their lives. 2 This number has increased by 643,000 Americans since 2004. 3
In 2008, 282,000 Americans over the age of twelve were dependant on
heroin.4 An estimated 5,000 to 10,000 intravenous drug users die of
overdoses every year.5
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Professor Megan LaBelle for her guidance in drafting this Note. Finally, the author
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throughout the writing process.
I. Office of National Drug Control Policy, Heroin Facts & Figures,
http://www.whitehousedrugpolicy.gov/DrugFact/heroin/heroinff.html (last visited Mar.
18, 2010) [hereinafter Heroin Facts & Figures]. See generally NATIONAL INSTITUTE ON
DRUG ABUSE, HEROIN ABUSE AND ADDICTION RESEARCH REPORT (National Institute on
Drug Abuse 2005) [hereinafter HEROIN ABUSE AND ADDICTION RESEARCH REPORT].
2. See OFFICE OF APPLIED STUDIES, 2008 NATIONAL SURVEY ON DRUG USE AND
HEALTH: NATIONAL FINDINGS Table G.1, Appendix G (HHS 2009) [hereinafter 2008
NATIONAL SURVEY ON DRUG USE AND HEALTH: NATIONAL FINDINGS], available at
http://www.oas.samhsa.gov/nsduh/2k8nsduh/2k8Results.cfm.
3.

Id

4. See generally id. The number of individuals who received treatment for heroin
addiction increased from 235,143 in 1997 to 246,871 just ten years later. Heroin Facts &
Figures, supra note I.
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Since the 1970s, the U.S. has directed its efforts toward establishing a
drug-free nation. 6 Unfortunately, the War on Drugs 7 has demonized drugs8
and those who abuse them, focusing on incarceration as the main deterrent.
Treatment methods that do not conform to this policy face extreme
opposition. 9 For example, methadone maintenance treatment (MMT) is

5. CDC, METHADONE MAINTENANCE TREATMENT 1 (2002), http://www.cdc.gov
/idu/facts/MethadoneFin.pdf [hereinafter METHADONE MAINTENANCE TREATMENT].

6. Anti-Drug Abuse Act of 1988, Public Law 100-690, 102 Stat. 4181 § 5251(b);
see also Kevin B. Zeese, Drug Policy in America - A Continuing Debate: Engaging the
DebateReform vs. More ofthe Same, 30 FORDHAM URB. L.J. 465, 481 (2003).
7. In 1971, President Nixon named drug abuse as "public enemy number one in the
United States" and announced the creation of the Special Action Office for Drug Abuse
Prevention (SAODAP), to be headed by Dr. Jerome Jaffe, a leading methadone treatment
specialist. See Frontline, Thirty Years of America's Drug War: a Chronology, Public
Broadcasting Company, http://www.pbs.org/wgbh/pages/frontline/shows/drugs/cron/
(last visited Mar. 18, 2010). The term "drug" is statutorily defined as:
(A) articles recognized in the official United States Pharmacopeia, official
Homoeopathic Pharmacopeia of the United States, or official National
Formulary, or any supplement to any of them; and
(B) articles intended for use in the diagnosis, cure, mitigation, treatment, or
prevention of disease in man or other animals; and
(C) articles (other than food) intended to affect the structure or any function
of the body of man or other animals; and
(D) articles intended for use as a component of any article specified in clause
A, B, or C.
Federal Food, Drug, & Cosmetic Act, 21 U.S.C. § 321(g)(1) (2009).
See also Drug Prevention & Control, 21 U.S.C. § 802(12) (2009) (providing "rt]he
term "drug" has the meaning given that term by section 321(g)(1) of this title"). A
controlled substance is "a drug or other substance, or immediate precursor, included in
schedule I, II, III, IV, or V of part B of this subchapter. The term does not include
distilled spirits, wine, malt beverages, or tobacco, as those terms are defined or used in
subtitle E of the Internal Revenue Code of 1986." 21 U.S.C. § 802(6). This Note will
refer to drugs as defined by 21 U.S.C. § 802(6), and will focus on opiates specifically.
8. Noah Mamber, Coke and Smack at the Drugstore: Harm Reductive Drug
Legalization: An Alternative to a CriminalizationSociety, 15 CORNELL J.L. & PUB. POL'Y
619, 626-40 (2006).
9. See generally 144 Cong. Rec. S12186 (daily ed. Oct. 9, 1998) (statements of
Sens. McCain, Coats & Coverdell); 134 Cong. Rec. E3101 (daily ed. Sept. 27, 1988)
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currently the nationally recognized treatment for heroin addiction; however,
it was ardently contested when it was introduced. 10
European nations facing similar problems with heroin addiction have
conducted a series of studies evaluating the effectiveness of heroin
maintenance treatment (HMT). 11 This type of treatment is a variant of MMT
that provides heroin addicts with controlled doses of pure heroin, instead of,
or in conjunction with, methadone, in a sterile and supervised setting.12 The
success of these studies generated interest in conducting a similar study in
North America. 13 This led to the North American Opiate Medication4
Initiative (NAOMI), a Canadian study modeled after the European studies.
NAOMI's successful results were published in the New England Journal of
Medicine in August, 2009.'5
When conceptualizing a North American HMT study, researchers were
discouraged by the stringent anti-drug laws of the United States because, in
their current form, they prohibit such a study. 16 However, five studies have

(statement of Rep. Clay). See also 146 Cong. Rec. S9094 (daily ed. Sept. 22, 2000)
(statement of Sen. Levin).
10. See generally 144 Cong. Rec. S12186 (daily ed. Oct. 9, 1998) (statements of
Sens. McCain, Coats & Coverdell); 134 Cong. Rec. E3101 (daily ed. Sept. 27, 1988)
(statement of Rep. Clay). See also 146 Cong. Rec. S9094 (daily ed. Sept. 22, 2000)
(statement of Sen. Levin).
11. Thomas V. Perneger et al., Randomised trial of heroin maintenance programme
for addicts who fail in conventional drug treatments, 317 BMJ 13 , 13-14 (1998); Wim
van den Brink et al., Medicalprescriptionof heroin to treatment resistant heroin addicts:
two randomized controlled trials, 327 BMJ 310 , 311 (2003); Christian Haasen et al.,
Heroin-assistedtreatmentfor opioid dependence, 191 British Journal of Psychiatry 55,
56 (2007); J.C. March et al, Controlled trial of prescribed heroin in the treatment of
opioid addiction,31 J. OF SUBSTANCE ABUSE TREATMENT 203, 204-05 (2006).

12. Perneger et al., supra note 11, at 13-14; van den Brink et al., supra note 11, at
311; Haasen et al., supra note 11, at 56; March et al, supra note 11, at 204-05.
13. Eugenia Oviedo-Joekes et al, Diacetylmorphine versus Methadone for the
Treatment of Opioid Addiction, 361 NEw ENG. J. MED. 777, 778 (2009).
14.

Id. at 778.

15.

Id.

16.

Id.
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been successfully conducted in other countries, which confirm the
effectiveness of HMT in treating heroin addiction.1 7 Thus, it is time for the
U.S. to explore the value of using HMT in rehabilitating the American
heroin-addicted population. The U.S. needs to encourage state legislation
that will promote an American study on the effectiveness of HMT. While
similar legislation has already been passed in several states, 18 the Supreme
Court's broad ruling20 in Gonzales v. Raich19 has discouraged any action

under the state laws.
This Note will argue that U.S. drug policy, particularly post-Raich, must
be revised to encourage state legislation that would allow an HMT study to
be conducted in the U.S. The first section will provide background
information on the severity of the heroin problem in the U.S. and relevant
statistics based on the current MMT procedure. Next, this Note will
describe the European and Canadian studies on HMT and their results. The
next section will discuss current U.S. drug laws and policies, how they stand
as a barrier to HMT, and will compare these policies to the harm-reduction
policies of Europe and Canada. Finally, this Note will discuss possible
adjustments to the current U.S. drug policy that would allow an HMT study
to be administered in this country. It will also address arguments that would
likely be raised in opposition to studying the effectiveness of HMT, as well
as recent developments under the Obama Administration that may lead to
further reform and support for an HMT study in America.

17. Perneger et al., supra note 11, at 13-14; van den Brink et al., supra note 11, at
311; Haasen et al., supra note 11, at 56 ; March et al, supra note 11, at 204-05.
18. Ariz. Rev. Stat. Ann. §13-3412.01 (2009). See also The National Organization
for the Reform of Marijuana Laws, Active State Medical Marijuana Programs, http:
//www.norml.org/index.cfm?Group_ID=3391 (last visited Mar. 18, 2010) [hereinafter
Active State Medical Marijuana Programs].
19.
20.
2005,

See generally Gonzales v. Raich, 545 U.S. 1 (2005).
Michael Kiefer, Court snuffs medicinal pot, THE ARIZONA REPUBLIC, Jun. 7,
at

IA,

available at

http://www.azcentral.com/health/wellness/articles/0607

medicalmj.html; Ruth C. Stern & J. Herbie DiFonzo, The End of the Red Queen's Race:
Medical Marijuana in the New Century, 27 QulNNIPtAc L.REv. 673, 720 n. 340 (2009);
Andrew J. Boyd, Medical Marijuana and PersonalAutonomy, 37 J. MARSHALL L. REv.
1253, 1260 (2004).
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I1. BACKGROUND

A. Heroin Statistics
Users seek out heroin for the immediate feeling of euphoria, which, for
intravenous users, takes seven to eight seconds to experience. 2 1 Other shortterm effects include a warm flushing of the skin, dry mouth, heavy
extremities, depression of the central nervous system that clouds mental
functioning, and slowed breathing, sometimes to the point of respiratory
failure. 22 The long-term effects that users can experience include collapsed
veins, infection of the heart lining and valves, abscesses, liver disease,

pulmonary complications (including various types of pneumonia), and, most
insidious, increased tolerance that
requires progressively larger doses to
23
regain the initial euphoric feeling.
Heroin users are at a particularly high risk for contracting Human

Immunodeficiency Virus (HIV),24 hepatitis C,25 and other infectious diseases
because they often share needles.
Additionally, they rarely know the
27
strength of the doses they self-administer, making overdoses more likely.

21.

HEROIN FACTS & FIGUREs, supra note 1.

22.

Id.

23.

Id

24. Human immunodeficiency virus (HIV) damages the immune system, interfering
with the body's ability to fight of disease and making the body more susceptible to
certain cancers and to infections that the body normally resists, such as pneumonia and
meningitis. There is no cure for HIV, and without treatment to control the virus, HIV can
progress to Acquired immunodeficiency syndrome (AIDS).
Mayo Clinic Staff,
Definition: HIV/AIDS, Mayo Clinic, http://www.mayoclinic.com/health/hiv-aids/
DS00005 (last visited Mar. 18, 2010).
25. Hepatitis C is a viral infection passed through contact with contaminated blood.
It is "one of several hepatitis viruses and is generally considered to be among the most
serious of these viruses." Hepatitis C attacks the liver and generally does not exhibit
symptoms in the early stages, but is detected decades after contraction when liver damage
is found in routine testing. Mayo Clinic Staff, Definition: Hepatitis C, Mayo Clinic,
http://www.mayoclinic.com/health/hepatitis-c/DS00097 (last visited Mar. 18, 2010).
26.

Heroin Facts & Figures, supra note 1.

27.

Id.
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28
The most common form of heroin available on the street is low-purity.
This form of heroin is dangerous because it is usually mixed with a variety
of substances, including sugar, starch, quinine, strychnine, and other poisons
that can be injurious if injected into the body. 29 In 2006, emergency
departments around the country reported 113 million visits, 189,780 of
which were related to heroin use.
In a 2008 survey, 13.3 percent of eighth graders, 17.2 percent of tenth
graders, and 25.4 percent of twelfth graders in the U.S. reported that heroin
was "fairly easy" or "very easy" to obtain. 31 Though abuse of other
substances is more prevalent, 32 the highly addictive nature and destructive
features of heroin addiction make it a serious problem in the U.S.

B. Methadone Treatment

The leading treatment for heroin addiction is MMT.33 Established in the
1970s, 34 MMT has been celebrated as the most effective tool against heroin
addiction. 35 Methadone occupies the opioid receptors in the addict's brain

28.

Id.

29.

Id.

30.

Id.

31.

Id.

32. In 2008, 4,199 Americans age twelve or older reported marijuana abuse, 1,716
reported abuse of pain relievers, 1,411 reported abuse of cocaine, and 282 reported abuse
of heroin. See 2008 NATIONAL SURVEY ON DRUG USE AND HEALTH: NATIONAL FINDINGS,
supra note 2, at 75 Figure 7.2. The number of heroin addicts increased from 2007 to
2008 by sixty-nine. See THE WHITE HOUSE, THE PRESIDENT'S NATIONAL DRUG CONTROL
STRATEGY ANNUAL REPORT 15 Figure 7 (2009) [hereinafter THE PRESIDENT'S NATIONAL
DRUG CONTROL STRATEGY ANNUAL REPORT], available at http://www.whitehouse
drugpolicy.gov/publications/policy/ndcs09/2009ndcs.pdf.
33.

METHADONE MAINTENANCE TREATMENT, supra note 5, at 1.

34.

OFFICE OF NATIONAL DRUG CONTROL POLICY, FACT SHEET, METHADONE (2000),

http://whitehousedrugpolicy.gov/publications/pdf/ncj 175678.pdf [Hereinafter
METHADONE].

35.

Id. See also METHADONE MAINTENANCE TREATMENT, supra note 5, at 1.
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36
and releases slowly enough that it need be taken only once a day.
However, methadone does not produce the euphoric sensation that the user
experiences with heroin. 37 Under MMT, the patient is still "physically
dependent on the opioid, but is freed from the
38 uncontrolled, compulsive, and
disruptive behavior seen in heroin addicts."
MMT is effective in treating heroin addiction. 39 The National Institute on
Drug Abuse (NIDA) reports that outpatients receiving MMT decreased their
weekly heroin use by sixty-nine percent, their criminal activity by fifty-two
40
percent, and increased their full-time employment by twenty-four percent.
Additionally, heroin addicts who are redirected from street use of
intravenous heroin to oral methadone are diverted from sharing needles and
engaging in illicit activities, such as robbery and prostitution. This
contributes to a decline in the spread of HIV and AIDS, hepatitis B and C,
and other sexually transmitted diseases. 4 '
However, there are serious limits to MMT. Even though the success rates
for MMT are impressive, only twenty percent of the estimated 810,000
heroin addicts in the U.S. were able to access this form of treatment in the
year 2000. 42 MMT clinics tend to administer low doses of methadone to
their patients (approximately thirty milligrams per day) 43 despite compelling
research finding that dosages should be determined on an individual basis,
and that most heroin addicts benefit from dosages between sixty to 120

36.

METHADONE, supra note

34.

37.

Id.

38.

Id.

39.

METHADONE MAINTENANCE TREATMENT, supra note 5, at 1.

40.

METHADONE,

41.

Id.

42.

Id.

43.

CENTER FOR DISEASE CONTROL, SUBSTANCE ABUSE TREATMENT FOR INJECTION

supra note 34.

DRUG USERS: A STRATEGY
gov/idu/facts/TreatmentFin.pdf

WITH MANY BENEFITS, 3 (2002), http://www.cdc.
[hereinafter SUBSTANCE ABUSE TREATMENT FOR

INJECTION DRUG USERS: A STRATEGY WITH MANY BENEFITS].
MAINTENANCE TREATMENT,

supra note 5, at 2.

See also METHADONE
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milligrams of methadone or more. 44 Research has shown that MMT requires
a minimum of twelve months to be effective, "and some opiate-addicted
individuals will continue to benefit from methadone maintenance treatment
over a period of years.' '4 5 Nevertheless, most MMT patients drop out of
their program well short of the necessary twelve-month period.46 This often
occurs because patients are expelled for failing to observe clinic regulations
or are persuaded to leave early by medical staff.47 Additional barriers to
MMT, such as inconvenient clinic locations, fees, forms to fill out, referral
requirements, waiting lists, lack of providers, and negative stereotypes that
create discouraging problems that impede
affect the treatment environment, 48
addicts who are seeking treatment.
Until recently, the Food and Drug Administration (FDA) regulated
methadone clinics, which had to obtain a license to operate. 49 States often
imposed stricter regulations than the FDA, and individual clinics frequently
instituted even more stringent protocols than required by the states for fear
of violating state or federal regulation. 50 In 2001, the MMT regulations
were reformed: methadone administration became regulated by the Center
for Substance Abuse Treatment (CSAT), an agency of the Substance Abuse
and Mental Health Services Administration (SAMHSA) under the U.S.
Department of Health and Human Services. 5 1 Additionally, clinics are no

44.

METHADONE MAINTENANCE TREATMENT, supra note 5, at 2.

45.

Id.

46.

Id.

47.

Id.

48.

SUBSTANCE ABUSE TREATMENT FOR INJECTION DRUG USERS:

A

STRATEGY WITH

MANY BENEFITS, supra note 43, at 3.
49.

NATIONAL

ALLIANCE

OF

METHADONE

ADVOCATES,

THE

NEW

FEDERAL

REGULATIONS: WHAT Do THEY MEAN FOR PATIENTS? (2003), http://www.methadone.

org/namadocuments/eslOnew federalregulations.html [hereinafter NATIONAL ALLIANCE
OF METHADONE ADVOCATES]; see also 1 STUART S. NAGEL, POLICY STUDIES REVIEW
ANNUAL, 128 (Sage Publications 1981) (explaining that the FDA categorized methadone
as an "Investigational New Drug," giving the FDA "mandate to license and inspect
clinics prescribing the drug").
50.

Id.

51.

Id.; See generally SUBSTANCE ABUSE TREATMENT FOR INJECTION DRUG USERS: A

STRATEGY WITH MANY BENEFITS, supra note 43.
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longer required to be licensed. 52 Instead, an accreditation program is used
that is expected to "improve the quality of care through a greater emphasis
on individualized treatment planning, increased medical supervision, and
assessment of patient outcomes. 5 3 The effects of the new regulation system
have not been reported yet; however, U.S. drug policy still needs to address
the untreated eighty percent of the heroin-addicted community.
III. EMPIRICAL RESEARCH ON HEROIN MAINTENANCE TREATMENT

A. The Swiss Study

Recent interest in HMT can be traced to a Swiss study conducted between
1995 and 1996.54 The study was open to individuals who had been residents
of Geneva since 1994, were twenty years of age or older; had been addicted
to intravenous heroin for more than two years; consumed opiates on a daily
basis; suffered social problems, poor health or both due to drug use; and had
55
undergone two or more previously unsuccessful attempts at drug treatment.
The study divided its eighty participants into two groups: one group would
be admitted to the HMT program immediately, and one group would be
placed on
a waiting list and given priority to enter the HMT program in six
56
months.
57
Patients came to the Geneva clinic three times a day for their treatment.
While in these facilities, medical professionals gave patients information on
safe intravenous injection practices. 58 The study participants were then

52.

NATIONAL ALLIANCE OF METHADONE ADVOCATES,

supra note 49; See generally

SUBSTANCE ABUSE TREATMENT FOR INJECTION DRUG USERS: A STRATEGY WITH MANY
BENEFITS,

53.

supra note 43.

NATIONAL ALLIANCE OF METHADONE ADVOCATES,

supra note 49; see generally

SUBSTANCE ABUSE TREATMENT FOR INJECTION DRUG USERS: A STRATEGY WITH MANY
BENEFITS,

supra note 43.

54.

See generally Pemeger et al., supra note 11.

55.

Id.at 13.

56. Id.at 13-14. Participants on the waiting list were encouraged to seek alternate
treatment options in the meantime, and were considered the study's control group. Id. at
14.

57.

Id.

58.

Id.
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allowed to inject heroin themselves.59 They were monitored for thirty
6
minutes following injection before they were allowed to leave the clinic.
Furthermore, "all patients received psychological counselling, HIV
prevention counseling,
social and legal support services, and somatic
61
primary care."
Six months after completion of the study, ten of the twenty-four subjects
in the control group were still using street heroin daily. 62 However, in the
experimental group, twenty-one of the twenty-seven participants reported
that they had not used any street heroin in the previous month.
The HMT
group also experienced social and societal benefits: mental health improved
in the experimental group, with severe depression decreasing in both groups,
64
"but severe anxiety decreas[ing] only in the experimental group."
Difficulty controlling anger and the number of suicide attempts also
decreased at a higher rate in the experimental group. 65 Furthermore,
experimental participants saw a sharp decrease in their reliance on "street
life," with a decrease in drug offenses, property damage, and illegal income
generators (such as drug dealing, commercial sex, and theft). 66 Even
"existence of the programme in an urban neighbourhood" did not cause any
67
measurable problems in the surrounding society.

59.

Id.

60.

Perneger et al., supra note 11, at 14.

61.

Id.

62. See id. at 15, Table 2. Data was collected from fifty-one patients total: twentyseven in the experimental group, and twenty-four in the "waiting list" control group.
Nineteen participants in the control group entered methadone maintenance while on the
waiting list, which provided researchers a comparison between HMT and MMT. Id. at
14.
63.

See id. at 15, Table 2.

64.

Id at 15.

65.

Id.

66.

Perneger et al., supra note 11, at 15.

67.

Id. at 17.
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B. Subsequent European Studies

The success of the HMT study in Switzerland inspired a series of studies

in the Netherlands, Germany, and Spain that sought to verify and replicate
the findings of the Swiss study.68 The Dutch and German studies were much
69
larger than the Swiss study, with 549 and 1,032 participants respectively.
The Spanish study, with a smaller participant group of sixty-two, was aimed
at testing the success of the earlier studies in the unique Spanish
population. 70 All
three were modeled closely after the Swiss study, with
71
some variations.
The subsequent European studies of HMT as heroin addiction treatment
confirmed Switzerland's findings: HMT "was significantly more effective"
than methadone treatment alone 72 in terms of improving health and social
functioning and decreasing illicit drug use.73 These studies confirmed the
earlier findings that long-term treatment is necessary for increased
improvement.
While researchers were not prepared to recommend HMT
as a "first-line" therapy, the European researchers were confident that HMT
was a "viable alternative treatment that should be made available to patients

68. Id.at 13-14; van den Brink et al., supra note 11, at 311; Haasen et al., supra note
11, at 56; March et al., supra note 11, at 204-05.
69.

See van den Brink et al., supra note 11, at 310; Haasen et al., supra note 11, at

56.
70. March et al., supra note 11, at 204-05. "Despite the evidence for the feasibility
and effectiveness of DAM [diacetylmorphine] prescription, the implementation of this
treatment within different cultural contexts faces political barriers that make it necessary
to validate those results on the local target population." Id. at 204.
71.

See id

72. van den Brink et al., supra note 11, at 311. See also Haasen et al., supra note 11,
at 59-60 (stating that "heroin-assisted treatment of people with severe opioid dependence
and treatment resistance more effectively improved health and reduced illicit drug use
than methadone maintenance treatment").
73. March et al., supra note 11, at 209 (finding "greater improvement in terms of
physical health, risk behavior for HIV infection, [and] street heroin use" in the
experimental group); Haasen et al., supra note 11, at 59 (finding decreased street use of
heroin in both groups, with a "more pronounced reduction in the heroin group").
74.

Haasen et al., supra note 1I, at 60.
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who, throughout their addiction, have not improved with other
approaches.' 5
A synthesis of the European studies on HMT supports the adoption of
Americans, claiming cultural and other
HMT programs in Europe.
fundamental differences, would need evidence pertaining to their own
unique drug culture. 76 Due to financial and logistical barriers that prevented
the implementation of an HMT program in the U.S., 77a study of the efficacy
of HMT in North America was conducted in Canada.
C. The CanadianStudy - NA OMI
Eligibility factors for inclusion in the Canadian NAOMI program were
similar to those for the European studies. 78 Participants were randomly

75. March et al., supra note 11, at 210. See also van den Brink et al., supra note 11,
at 312 (noting that the "study provides strong evidence of the efficacy of prescribed
heroin for addicts who are resistant to other forms of treatment"); Haasen et al., supra
note 11, at 61 (recognizing "strong further evidence of the efficacy of prescribed heroin
in the treatment of people with opioid dependence who have not profited from other
forms of treatment").
76.

See generally Virginia Berridge, Heroin Prescription and History, 361 NEW

ENG. J. MED. 820 (2009).

77. Oviedo-Joekes et al., supra note 13, at 777 (stating that "[b]ecause of financial
and logistical barriers in the United States, the trial could be conducted only in Canada").
78. Eligible participants were those whose opioid dependence met three or more of
the seven criteria listed in the DSM-IV, who were twenty-five years of age or older, had
used opiates for at least five years, injected opiates daily, had not changed their city of
residence for at least one year, had attempted a minimum of two previous treatments for
opioid dependence ("including at least one attempt at methadone maintenance treatment
in which they received 60 mg or more of methadone daily for at least 30 days during a
40-day period"), and had not been part of a methadone maintenance treatment for at least
six months prior to being part of this study. Id. at 778. The DSM-IV defines substance
dependence as:
a maladaptive pattern of substance use leading to clinically significant
impairment or distress, as manifested by three (or more) of the following,
occurring any time in the same 12-month period:
1. Tolerance, as defined by either of the following:
(a) A need for markedly increased amounts of the substance to achieve
intoxication or the desired effect or
(b) Markedly diminished effect with continued use of the same amount of the
substance.
2. Withdrawal, as manifested by either of the following:

The Journalof Contemporary Health Law and Policy Vol. XXVI:2

assigned to three groups: 115 participants would receive diacetylmorphine
(heroin), 111 would receive methadone, and twenty-five would receive
hydromorphone. 79 The experimental group received a maximum daily dose
of 1,000 milligrams intravenous heroin, which was "self-administered under
supervision in the treatment clinics up to three times daily." 80 Experimental
subjects were monitored for fifteen minutes before and thirty minutes after
injection, and could change8 1 their treatment plans to partial or total use of
oral methadone at any time.
The results of the Canadian study were evaluated for two primary
outcome measures: "retention in addiction treatment at 12 months" 82 and

(a) The characteristic withdrawal syndrome for the substance or
(b) The same (or closely related) substance is taken to relieve or avoid
withdrawal symptoms.
3. The substance is often taken in larger amounts or over a longer period than
intended.
4. There is a persistent desire or unsuccessful efforts to cut down or control
substance use.
5. A great deal of time is spent in activities necessary to obtain the substance,
use the substance, or recover from its effects.
6. Important social, occupational, or recreational activities are given up or
reduced because of substance use.
7. The substance use is continued despite knowledge of having a persistent
physical or psychological problem that is likely to have been caused or
exacerbated by the substance (for example, current cocaine use despite
recognition of cocaine-induced depression or continued drinking despite
recognition that an ulcer was made worse by alcohol consumption).
AMERICAN PSYCHIATRIC ASSOCIATION, SUBSTANCE RELATED DISORDERS IN DIAGNOSTIC

AND STATISTICAL MANUAL OF MENTAL DISORDERS 191, 197-98 (2009).

79. Oviedo-Joekes et al., supra note 13, at 778. Hydromorphone is an opioid
analgesic used to treat moderate to severe pain. It is listed under Schedule II of the
Controlled Substances Act. DRUG ENFORCEMENT AGENCY, HYDROMORPHONE (2007),
http://www.deadiversion.usdoj.gov/drugs-concem/hydromorphone.htm.
80.

Oviedo-Joekes et al., supra note 13, at 778.

81.

Id. at 778-79.

82. Id. at 779 (defining outcome as "receipt of the study medication on at least 10 of
the 14 days before the 12-month assessment, or confirmation of retention in any other
treatment program or abstinence from opioids during this interval.").
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"reduction in illicit-drug use or other illegal activities." 83 Researchers have
determined that "[t]he rate of retention in treatment for addiction was 87.8"
percent for the heroin group and 54.1 percent for the methadone group. 84 In
the heroin group, sixty-seven percent of participants confirmed decreased
illicit-drug use or illegal activity, compared to 47.7 percent in the methadone
group.85 The average number of days that participants used street heroin in
the prior month decreased "from 26.6 to 5.3 in the diacetylmorphine
[heroin]
86
group and from 27.4 to 12 in the methadone group."
The Canadian study comports with the European studies, implying that
the findings in favor of HMT in Europe may be translated to North
American populations. The Canadian researchers, like their European
colleagues, concluded that "[t]he diacetylmorphine [heroin] group had
greater improvements with respect to medical and psychiatric status,
economic status, employment situation, and family and social relations...
suggest[ing] a positive treatment effect beyond a reduction in illicit-drug use
or other illegal activities."87 Although replication and cost-utility studies
would provide more solid support, the Canadian study provides a strong
argument for reforming drug policy in North America.
D. The Aftermath of the EuropeanStudies
Switzerland has continued operating HMT centers since the initial study
in 1995. 88 Today, there are twenty-three centers throughout Switzerland that
administer prescription heroin to nearly 1,300 addicts under strict
supervision. 89 As in the initial study, these centers supplement heroin
addiction treatments with psychiatric and social counseling.90 The centers

83.

Id.

84.

Id. at 780.

85.

Id.

86.

Oviedo-Joekes et al., supra note 13, at 781.

87.

Id. at 784.

88. Associated Press, A glance at heroin laws aroundEurope, AOL NEWS, Dec. 1,
2008, http://www.aol.co.nz/news/story/A-glance-at-heroin-laws-around-Europe/1366751 /
index.html.
89.

Id.

90.

Id.
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operate under special authorization from the Swiss Federal Office of Public
Health. 9'
The Swiss officials in charge of the national HMT program are required to
submit an annual report that provides the most recent statistics of the
program. 92
The reports define elements that will be considered in
determining whether the program has been successful, including: sustained
commitment to treatment, improvement in physical and mental health,
progress in social integration, and permanent abstinence from opiate
consumption. 93 The 2007 report found that more than seventy percent of all
HMT patients (who are considered to be treatment-resistant) stayed in the
program for one year and almost sixty percent stayed for two or more
years. 94 Indeed, the average retention rate for participants in the HMT
programs in Switzerland is approximately three years. 95 Evidence implied
that mental stress in HMT patients decreases during treatment. 96 Promising

91.
MARTIN BOECHI & UELI MINDER, Swiss Drug Policy: Harm Reduction and
Heroin-SupportedTherapy, FRASER INSTITUTE DIGITAL PUBLICATION, 2001 at 6, available

at

http://oldfraser.lexi.net/publications/books/drug_papers/UDBuechiMinder.pdf

(explaining that Swiss federal law prohibits the use of opium, heroin, hallucinogens, and
cannabis except "for scientific research and for limited medical purposes. A special
authorization from the Swiss Federal Office of Public Health is required for all
substances and for all purposes").
92.

FEDERAL

DEP'T

TREATMENT/TREATMENT

[hereinafter

OF

HOME

AFFAIRS

ET

AL.,

HEROIN-ASSISTED

(HAT) IN 2007, 1 n. 1 (2008)
TREATMENT/TREATMENT WITH DIACETYLMORPHINE (HAT)

WITH DIACETYLMORPHINE

HEROIN-ASSISTED

IN2007]. "This report is written every year and submitted to the Federal Council pursuant
to Article 16, Paragraph 1(g) of the Ordinance concerning the Medical Prescription of
Heroin of 8th March 1999." Id.
93.

Federal Office of Public Health (FOPH), Heroin-Assisted Treatment (HAT)

http://www.bag.admin.ch/themen/drogen/00042/00629/00798/0119/index.html?lang=en.
94.

HEROIN-ASSISTED TREATMENT/TREATMENT

2007, supra note 92, at 12.
95. Id.
96.

Id. at 13.

WITH DIACETYLMORPHINE

(HAT)

IN
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statistics also show significant improvement in social
integration for HMT
97
patients who are in treatment for at least one year.
In 2003, a study reported the results of a survey of sixty-four percent of
the 175 patients enrolled in an HMT program between January, 1994 and
March, 1995 and had left their programs.
Of these, 111 patients reported
having completed either a methadone treatment or an abstinence-oriented
therapy, and sixteen percent of those 111 patients reported that they had
been abstinent from opiate use in the six months prior to the survey.99
The 2007 report found that new enrollment in Swiss HMT programs has
been decreasing steadily since 2002, from 300 enrollments that year to 130
in 2007.10 Furthermore, the median age of newly enrolled HMT patients
has increased from 30.8 in 1994 to thirty-eight in 2007.101 Officials inferred
from these statistics that "fewer persons in general and above all only a few
very young persons are today seriously heroin dependent."'' 0 2 This inference
is supported by a 2006 study that found that heroin consumption in Zurich
had risen "from 80 persons in 1975 to 850 persons in 1990 and dropped back
to 150 in 2002," a decrease of four percent per year. 10 3 Swiss health surveys
also indicate "a decrease in experience of heroin consumption among 15 to
39 year olds from 1.3% in 1992 to 0.9% in 2002. " 1°4 In late 2008, in light
of such promising statistics, sixty-eight percent of voters supported a plan to
incorporate the
prescription heroin program into the national health policy
05
permanently.1

97. Id. at 17. "Patients who have been in treatment for at least one year are more
likely to have stable living arrangements (96%) and to live alone (58%) than new
enrollments (73% and 46% respectively)." Id. at 17.
98.

Id.

99. Id. The survey also showed a significant decrease in patients' concomitant use of
other substances. HEROIN-ASSISTED
(HAT) IN 2007, supra note 92, at 18.

100. Id. at 7.
101.

Id.

102.

Id.

103.

Id. at 11.

104.

Id.

TREATMENT/TREATMENT

wiTH DIACETYLMORPHINE
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In mid-2009, the German Parliament followed suit, passing a law allowing
the prescription of heroin to "long-term users who fail to respond to other
treatments

.

. [who are] aged 23 or over ... have been addicted for at least

five years and have undergone two unsuccessful rehabilitation programmes.
. .,,106 Unlike the Swiss scheme, the German law will allow qualifying
addicts to receive their prescriptions over the counter rather than in a
clinic.'7

The Netherlands, like Switzerland, has continued operating its fifteen
HMT clinics since 2006, serving nearly 600 patients.10 8 New studies have
been initiated in Britain and Belgium.10 9 In February, 2008, the Danish
Parliament approved a two-year pilot scheme for prescription heroin
programs."° The Danish program will administer heroin and methadone in
combination to approximately 500 "of the worst affected and most
marginalized addicts in the country."''
Nations throughout Europe have not only recognized the validity of HMT,
but have enacted legislation to make HMT available to its heroin-addicted
populations. In the U.S., the Controlled Substances Act (CSA) and court
rulings seem to stand as obstacles to similar legislation that might benefit

105.

Swiss

approve

prescription

heroin,

BBC

NEWS,

Nov.

30,

2008,

http://news.bbc.co.uk/2/hi/europe/7757050.stm.
106.

German parliament approves heroin law, EURONEWS,

May

29,

2009,

http://www.euronews.net/2009/05/29/german-parliament-approves-heroin-law/.
107. Id. See also van den Brink et al., supra note 11, at 310 (reporting that in Danish
study, modeled after Swiss study, "[p]articipants . . . were not allowed to take any
[heroin] home").
108. Associated Press, A glance at heroin laws around Europe, AOL NEWS, Dec. 1,
2008, http://www.aol.co.nz/news/story/A-glance-at-heroin-laws-around-Europe/1366751/
index.html.
109.

Id.

110. AFP, Danish Parliament Approves Heroin Prescription Scheme for Worst
Addicts, MEDINDIA, Feb. 26, 2008, http://www.medindia.net/news/Danish-Parliament-

Approves-Heroin-Prescription-Scheme-for-Worst-Addicts-33453-1 .htm; AP, A glance at
heroin laws around Europe, AOL NEWS, Dec.

1, 2008,

http://www.aol.co.nz/

news/story/A-glance-at-heroin-laws-around-Europe/I 36675 /index.html.
111.

AFP, supra note 110.
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American heroin addicts. 112 However, minor changes in the federal drug
control legislation and greater federal trust in the actions of state
governments could pave the way for HMT in the U.S.
IV. U.S. DRUG POLICY: A BARRIER OR A SMOKE-SCREEN?
The U.S. declared war on illicit drugs in the 1980s, vowing to eradicate
drug use inside its borders within ten years." 13 Almost thirty years later, the
U.S. drug problem is still a stark and destructive reality. Recently, the U.S.
government found seven million Americans114 who meet the established
standards for illicit drug abuse or dependence.
Thanks to its policies and programs, the President's National Drug
Control Strategy (NDCS) boasts significant decreases in youth drug use for a
number of illegal drugs during the period between 2001 to 2008; though,
notably, the only drug whose use did not decrease was heroin. 115 The NDCSl 6
is concerned with alcohol use and a wide range of illegal drug use.'
However, it is mainly focused on marijuana, which it has identified as not
only an important gateway drug to more serious substance abuse, but also a
risk in and of itself due to a recently researched link between marijuana use
and mental illness. 117 This11broad
focus results in minimized attention for
8
heroin abuse and treatment.

112.

See infra Sec. IV.

113.

Anti-Drug Abuse Act of 1988, Public Law 100-690, 102 Stat. 4181, § 5251(b)

(1988). See also Kevin B. Zeese, Drug Policy in America - A Continuing Debate:
Engaging the Debate Reform vs. More of the Same, 30 FORDHAM URB. L. J. 465, 481

(2003).
114.

THE PRESIDENT'S NATIONAL DRUG CONTROL STRATEGY ANNUAL REPORT, supra

note 32, at 1.
115.

Id.at2,Fig.2.

116.

Id. at2.

117. Id. See Figure 2 (describing change in "youth drug use" from 2001 to 2008,
including alcohol, cigarettes, and illegal substances). Id. at 2.
118.

See generally id. (emphasizing marijuana and other illicit drugs).
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A. The War on Drugs in Action: Criminalizationand the Controlled
Substances Act
The U.S. drug policy is known for its emphasis on criminalization 1 19 In
2007, approximately 1,841,200 Americans were arrested for drug-related
offenses at the state or local level; 82.5 percent of these were for
possession. 120 In 1995, only twenty-three percent of adult probationers were
released on the condition of seeking substance abuse treatment. 11 In 2002,
22
fifty-three percent of inmates were dependent on or had abused drugs.
However, only 16.9 percent of these individuals received treatment while
incarcerated. 123 In 2009, the U.S. National Drug Control Budget spent 3.65
billion dollars on domestic law enforcement and 3.84 billion on interdiction,
compared to 3.42 billion dollars on treatment and 1.79 billion on
prevention. 124 In 2010, the budget will increase by 251 billion dollars for
domestic law enforcement and interdiction, 25
and will decrease by thirty-nine
billion dollars for treatment and prevention.'
The main legislation through which the War on Drugs is waged is the
CSA. 126 Enacted in 1970, the CSA recognizes that drug abuse has "a
substantial and detrimental effect on the health and general welfare of the

119.

Mamber, supra note 8, at 620-22.

120. See Bureau of Just. Stat. Drugs and Crime Facts, http://bjs.ojp.usdoj.gov
/content/dcf/contents.cfm (last visited Mar. 18, 2010).
121.

THOMAS P. BONCZAR CHARACTERISTICS OF ADULTS ON PROBATION,

1995 7 (DOJ

1997), http://bjs.ojp.usdoj.gov/content/pub/pdf/cap95.pdf.
122.

JENNIFER C. KARBERG & DORIS J. JAMES SUBSTANCE DEPENDENCE, ABUSE, AND

TREATMENT OF JAIL INMATES,

2002 3, 8 (DOJ 2005), http://bjs.ojp.usdoj.gov/content

/pub/pdf/sdatji02.pdf.
123.

Id.

124.

OFFICE OF NATIONAL

DRUG CONTROL

POLICY NATIONAL

DRUG

CONTROL

BUDGET: FY 2010 BUDGET HIGHLIGHTS 2, Fig. 1 (2009), http://www.wilsoncenter.
org/news/docs/fy I0budget.pdf.
125. Id.The 2010 budget allots 3.737 billion dollars for domestic law enforcement
and approximately four billion dollars for interdiction, an increase of eighty-three million
dollars and 168 million dollars, respectively. Id.
126.

Drug Abuse Prevention & Control, 21 U.S.C. § 801 (2009).
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American people," and, therefore, legitimizes federal control of drug
manufacture and distribution under Article
1, Section 8, Clause 3 of the U.S.
27
Constitution-the Commerce Clause.1
The CSA established five schedules of controlled substances. 28 These
schedules graduate in gravity from Schedule V, drugs that have low
potential for abuse and have currently accepted medical use in treatment in
the United States,' 29 to Schedule I, drugs that have a high potential for abuse
and have "no currently accepted medical use in treatment in the United
3
Heroin is currently listed as a Schedule I substance.' '
States."' 30
Methadone, a synthetic form of heroin and the foundation of MMT, is
categorized as a Schedule I substance, 132 indicating a high potential for
abuse and "a currently accepted medical use in treatment in the
United
133
States or a currently accepted medical use with severe restrictions."'
B. InternationalIssues: Treaty Obligationsand InternationalDrug Policies
The U.S. also justifies the enactment of the CSA by relying on its
obligations as a party to the Single Convention on Narcotic Drugs
(Convention). 34 The Convention requires that member states "adopt such
measures as will ensure that [drug abuse and trafficking] . . . shall be
punishable offences when committed intentionally, and that serious offences
shall be liable to adequate punishment
particularly by imprisonment or other
' 35
penalties of deprivation of liberty."'

127.

Id. at §§ 801(1)-(6) (2009). See also U.S. CONST. art. 1, § 8, cl. 3.

128.

21 U.S.C. § 812.

129.

Id at §§ 812(b)(5)(A)-(B).

130. Id. at § 812(b)(1)(B).
131.

Id. at § 812(c) Schedule I (b)(10).

132. Id. at § 812(c) Schedule II (b)(1 1). "Methadone is a synthetic agent that works
by 'occupying' the brain receptor sites affected by heroin and other opiates."
METHADONE MAINTENANCE TREATMENT, supra note

5, at 1.

133.

Drug Abuse Prevention & Control, 21 U.S.C. §§ 812(b)(2)(A)-(B) (2009).

134.

Drug Abuse Prevention & Control, 21 U.S.C. § 801(7) (2009).

135. Single Convention on Narcotic Drugs, Art. 36(1)(a), Mar. 30, 1961, 18 U.S.T.
1407, 520 U.N.T.S. 204 (amended by protocol, 26 U.S.T. 1439, 976 U.N.T.S).
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The Convention utilizes a schedule organization of drugs similar to that
found in the CSA. 136 Under the Convention's organization, both heroin and
methadone are listed under Schedule 1.137 Notably, the Convention obliges
signatories to "take such legislative and administrative measures as may be
necessary . . . [s]ubject to the provisions of this Convention, to limit
exclusively to medical and scientific purposes the production, manufacture,
'1 38
export, import, distribution of, trade in, use and possession of drugs."
Additionally, the Convention requires that drugs under Schedule I be
manufactured only by those granted a license to do so, except if carried out
by a state enterprise. 139 The Convention's limitations on Schedule I drugs
reflect recognition that even these dangerous substances could have medical
and scientific value, and should be available for use accordingly. The U.S.,
however, has precluded that possibility for drugs categorized under Schedule
I of the CSA. 14
Also party to the Convention are Switzerland, the Netherlands, Germany,
Spain, and Canada-the sites of successful HMT studies throughout the past
fifteen years. 14 This would imply that signatories' obligations under the
Convention do not preclude them from conducting a study of a serious
drug's medical value. Since these nations and the U.S. share the same
obligations under the Convention, it is puzzling that U.S. drug laws are so
much more stringent than Canadian and European drug laws to the point of
barring an HMT study within its own borders.
The difference between U.S. and European drug laws is best explained by
the diversity in policies. European nations, with cooperation in European

136.

Id.

137.

Id.at Schedules.

138.

Id. at Art. 4(c) (emphasis added).

139.

Id. at Art. 29 (1).

140. Drug Abuse Prevention & Control, 21 U.S.C. § 812(b)(l)(B-C) (2009). See also
Single Convention on Narcotic Drugs, supra note 119, at Art. 39 (permitting states to
adopt "measures of control more strict or severe than those provided by this
Convention").

141. Single Convention on Narcotic Drugs, supra note 135, at Final Act of the United
Nations Conference for the Adoption of a Single Convention on Narcotic Drugs, para. 3.
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142

Union (E.U.) legislation, support a harm-reduction model of drug control.
This policy focuses on drug addiction and abuse as a public health concern,
rather than a criminal issue. 143 The Maastricht Treaty, the first major E.U.
treaty to refer specifically to the drug phenomenon, stipulates in Article 129
that "community action shall be directed towards the prevention of diseases,
in particular the major health scourges, including drug dependence, by
promoting research into their causes and their transmission, as well as health
information and education." ' 144 Though specific health initiatives and
activities are left to the individual European nations to direct, the1 45adopted
view of the E.U. generally emphasizes education and public health.
Although Canada's drug policy once mirrored the criminalization model
of the U.S., it is now moving toward the European approach of harmreduction.146 A prime example of this change is the 1.5 million dollars the
Canadian government is providing to support scientific evaluation of a safe-

142. See generally International Harm Reduction Network Global State of Harm
Reduction: Western Europe, http://www.ihra.net/WestemEurope#HarmReductionPolicies
(last visited Mar. 18, 2010).
143. Drug Policy Alliance Network, Reducing Harm: Treatment and Beyond
http://www.drugpolicy.org/reducingharm/ (last visited Mar. 18, 2010) [hereinafter
Reducing Harm: Treatment and Beyond].
144. Treaty on European Union, art. 129, Feb. 7, 1992, 1992 O.J. (C191) 1, 31 I.L.M.
available at http://eur-lex.europa.eu/en/treaties/dat/l 1992M/htm/
253
(1992),
l1992M.html#0001000001. (emphasis added). See European Legal Database on Drugs
Union,
http://eldd.emcdda.europa.eu/html.cfm/
European
Country
Profiles:
index5l74EN.html?sLanguagelSO=EN&nNodelD=5174# (last visited Mar. 18, 2010)
(stating that "[t]he Maastright Treaty was the first European Treaty which specifically
referred to the drug phenomenon.").
145.

European Legal Database on Drugs Country Profiles, supra note 144.

146. Drug Policy Alliance Network Drug Policy Around the World: Canada,
http://www.drugpolicy.org/global/drugpolicyby/northamerica/canada/ (last visited Mar.
18, 2010). As enacted, Canadian drug laws recognize the possibility of medicinal or
scientific value of even Schedule I substances. For instance:
The Minister may, on such terms and conditions as the Minister deems
necessary, exempt any person or class of persons or any controlled substance or
precursor or any class thereof from the application of all or any of the
provisions of this Act or the regulations if, in the opinion of the Minister, the
exemption is necessary for a medical or scientific purpose or is otherwise in the
public interest.
Controlled Drugs & Substances Act, 1996 S.C., Part VI, Para.56 (Can.).
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injection drug site in Vancouver over a three-year period.'4 7 The U.S.
aversion to a harm-reduction approach to drug control was very clear in the
Bush Administration's drug czar, John Walters', response to Canada's
support of safe-injection drug sites, sugesting that such sites would amount
to "state-sponsored personal suicide.

V. LEGISLATIVE SOLUTIONS AND POLITICAL OBSTACLES

The European and Canadian studies on HMT bring to light important and
relevant insight for the U.S.'s heroin-addicted population. While MMT
continues to be successful for some heroin addicts, a significant number of
addicts never receive MMT.149 Even with the use of MMT, changes in the
number of individuals who are addicted to heroin addiction are minimal at
best. 50
American heroin addicts could benefit greatly from HMT.
However, significant barriers exist in the form of strict anti-drug legislation
and extremely prejudicial attitudes towards illicit drug use in the U.S."' An
HMT study must be conducted in the U.S. to validate the international
results and utilize them in U.S. drug policy. To do so, the U.S. must adjust
its drug laws and overcome significant moral, political, and normative
opposition from its citizens.

147.

Reducing Harm: Treatment and Beyond, supra note 143.

148. Naomi Klein, Canada: Hippie Nation? THE NATION, July 21, 2003, at 12,
available at http://www.thenation.com/doc/2003072 1/klein. John Walters served as drug
czar from 2001-2009. Office of National Drug Control Policy John P. Waiters,
http://www.whitehousedrugpolicy.gov/about/director bio b.html (last visited Mar. 18,
2010). Walters was succeeded by Gil Kerlikowske. Office of National Drug Control
Policy Staff Bios: R. Gil Kerlikowske, http://www.whitehousedrugpolicy.gov/about
/director.html (last visited Mar. 18, 2010).
149.

METHADONE,

supra note 34;

THE PRESIDENT'S NATIONAL

DRUG CONTROL

STRATEGY ANNUAL REPORT, supra note 32, at 2, Fig. 2.
150.

METHADONE,

supra note 34;

THE PRESIDENT'S NATIONAL

DRUG CONTROL

STRATEGY ANNUAL REPORT, supra note 32, at 2, Fig. 2 (indicating no change in youth

heroin use between 2001 and 2008).
151.

See discussion infra Part V.A.

2010

Heroin Maintenance Treatment

A. FederalLegislation: Amending the Scheduling ofHeroin in the CSA
Currently, the CSA does not recognize any medical value in heroin.152 In
fact, the CSA does not even recognize that heroin can be safely used under
medical supervision, as it would be in HMT.153 As the law currently stands,
it is a significant obstacle, if not a complete bar, to an HMT study.
However, if heroin's categorization under the CSA were amended from
Schedule I to Schedule II, where its medical value154could be recognized, an
HMT study could be conducted legally in the U.S.
The CSA is updated and republished annually 155 and provides explicit
procedures for amending the placement of a drug within a given schedule.,56
The Attorney General may hold a hearing to amend the scheduling of a drug
"(1) on his own motion, [(2)] at the request of the Secretary [of Health and
Human Services], or [(3)] on the petition of any interested party." 157 Before
conducting such proceedings, the Attorney General must ask for a scientific58
and medical evaluation and seek a recommendation from the Secretary.
The Secretary's evaluation and recommendation will consider any scientific
evidence available regarding the drug's pharmacological effect, the "state of
current scientific knowledge regarding the drug . . . " any risk to public
health, the drug's "psychic or physiological dependence liability," and
"whether the substance is an immediate precursor of a substance already
controlled."' 59 Additionally, the Secretary will consider the scientific and
medical considerations related to the drug's "actual or relative potential for
abuse;" its history and "current pattern of abuse;" and "[t]he scope, duration,

Abuse Prevention & Control, 21 U.S.C. § 812(b)(1)(B) (2009).

152.

Drug

153.

Id. at § 812(b)(1)(C).

154.

See id. at § 812(b)(2).

155.

Id. at § 812(a).

156.

Drug

157.

Id.at § 811(a).

Abuse Prevention & Control, 21 U.S.C. § 811 (2009).

158. Id at § 811(b).
159.

Id. at §§ 811(b)-(c).
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scientific and medical
The Secretary's
and significance of abuse."' 160
16 1
findings are binding on the Attorney General.
Considering these factors, the Secretary could conceivably recommend
that heroin be reclassified from a Schedule I to a Schedule 1I narcotic.
Although heroin poses a high risk of dependence and abuse, methadone does
as well. 62 Methadone is categorized in Schedule I because it is recognized
' 163
despite
as having an "accepted medical use ... with severe restrictions,
the fact that abuse of methadone "may lead to severe psychological or
The gravity and dangers of heroin use and
physical dependence."' 64
methadone use are so similar that it appears arbitrary to place one in a more
restrictive schedule than the other.
According to the CSA, placement of a drug within any given schedule is
prohibited "unless the findings required for such schedule are made with
respect to such drug or other substance.' 65 Substantial evidence exists in
support of removing heroin from Schedule I and adding it to Schedule II.
European and Canadian studies on HMT have provided scientific proof that
heroin, in the restricted scope of maintenance treatment, has a positive
166
pharmacological effect in addiction treatment.
1. Benefits - "Legalization" of HMT and the 2001 MMT Regulation
Reforms
By moving heroin from Schedule I to Schedule IIof the CSA, the U.S.
government would establish that heroin could be used medicinally in HMT
Substances in Schedule II have a "currently accepted
administration.
medical use in treatment in the United States or a currently accepted medical
use with severe restrictions," despite a "high potential for abuse" and a

160.

Id. at § 811 (b).

161.

Id.

162.

See supra discussion at Sec. II.

163. Drug Abuse Prevention & Control, 21 U.S.C. § 812(b)(2)(B) (2009); see also 21
U.S.C. § 812, Schedules, (b)(1 1).
164.

21 U.S.C. § 812(b)(2)(C).

165.

Id.at § 812(b).

166. See generally Haasen et al., supra note 11; van den Brink et al., supra note 11;
Perneger et al., supra note 11.
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finding that "[a]buse of the drug or other substances may lead to severe
psychological or physical dependence." 167 Under that definition, the
government would have broad discretion to regulate medically administered
heroin. For example, the FDA has not approved methadone for use in pain
management, and "[a]s of January 1, 2008, manufacturers of 40 milligram
methadone hydrochloride dispersible tablets have voluntarily agreed to
restrict distribution of this formulation to only those facilities authorized for
detoxification and maintenance treatment of opioid addiction, and
hospitals."1' 68 As such, medicinal use of methadone is restricted almost
exclusively to addiction treatment. Use of medicinal heroin could be
similarly restricted to HMT clinics.
The 2001 reform of the methadone regulations provides an optimal model
for regulation of heroin for HMT purposes. 169 The Center for Substance
Abuse Treatment (CSAT) is currently overseeing the accreditation system
for MMT clinics and the use of methadone in those clinics.' 7' The CSAT
could regulate HMT clinics the same way it regulates MMT clinics.
Although the effects of the 2001 regulation reform are not yet known, the
existence of an established program that could be used as a model in
implementing HMT regulation is promising.
2. Obstacles - HistoricallyNegative Treatment of Heroin
Legislative changes do not occur in a vacuum. Any amendments to the
CSA would need to overcome substantial moral, political, and normative
opposition.1 71 The legislative debate over heroin control is not new. In
1924, Congress held impassioned hearings to discuss amendments to the
1914 Harrison Narcotics Act, 172 which had banned recreational use of

167.

21 U.S.C. § 812(b)(2).

168.

DRUG ENFORCEMENT

ADMINISTRATION, DRUGS AND CHEMICALS OF CONCERN:

(DOJ 2009), http://www.deadiversion.usdoj.gov/drugsconcern/
methadone/methadone.htm.
METHODONE

supra note 49.

169.

NATIONAL ALLIANCE OF METHADONE ADVOCATES,

170.

Id.

171.

See March et al., supra note 11, at 204 (stating that "[d]espite the evidence for

the feasibility and effectiveness of DAM [diacetlmorphine] prescription, the
implementation of this treatment within different cultural contexts faces political barriers
that make it necessary to validate those results on the local target population.").
172.

1914 Harrison Narcotics Act, 63 P.L. 223; 63 Cong. Ch. 1; 38 Stat. 785 (1914).
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narcotics.' 73 The proposed amendments, which would have restricted the
use of heroin exclusively for medicinal purposes, were thwarted by moral
arguments and sensational claims that tended to misconstrue, or even ignore,
relevant facts that would undermine the amendments. 74 The Harrison Act
was replaced by the Comprehensive Drug Abuse Prevention and Control Act
in 1970,175 which established the Controlled Substance Act and its schedules
of controlled substances. 76 As soon as 1980, challenges to the CSA's rigid
controls emerged.1 77 Congressman Stephen Neal (D-NC), in a discussion
with a panel of cancer researchers regarding the medicinal value of
marijuana and heroin in pain management, posited that:
we need more study, but to get the study, we need a substance
available to you to study, but as long as it's under Schedule 1, it will
not be available, because the assumption will be that there is no
medical use. It's a Catch-22 situation, it seems to me.178
Despite evidence of heroin's medical value,' 79 and an apparent
willingness by the public to accept at least controlled medicinal uses for

173. See generally A Bill Prohibitingthe Importationof Crude Opiumfor the Purpose
of Manufacturing Heroin, Hearings Before the H.R. Comm. On Ways and Means, on
H.R. 7079, 68th Cong. (1924).
174. See Suzanne Marcus Stoll, Why Not Heroin? The Controversy Surrounding the
Legalization of Heroin for Therapeutic Purposes, 1 J. CONTEMP. HEALTH L. & POL'Y,
173, 176-77 (1985).
175. Comprehensive Drug Abuse Prevention and Control Act in 1970, 91 P.L. 513; 84
Stat. 1236 (1970).
176.

Stoll, supra note 174, at 177.

177. See generally Health Consequences of Marijuana Abuse: Recent Findings and
the Therapeutic Uses of Marijuana and the Use of Heroin to Reduce Pain, H.R. Rep. 962-5 (1980).
178.

Id. at 32.

179. Pemeger et al., supra note 11, at 13-14; van den Brink et al., supra note 11, at
311; Haasen et al., supra note 11, at 56; March et al, supra note 11, at 204-05; OviedoJoekes et al., supra note 13, at 777.
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heroin," 8 Congress continues to perpetuate "a model
' 81of drug control more
suited to law enforcement than to medical concerns."'
In the early 1970s, when heroin addiction was reaching its peak, New
York City briefly considered instituting an HMT program. 182 The initial
plans for treatment were far below the standards modem research has
established, 183 but the public opposition focused on far more dramatic
points. Harlem's Congressman Charles Rangel (D-NY) urged the American
people to "open up their eyes and recognize heroin for what it is - a killer,
not a drug on which a human being should be maintained."' 84 The head of
the Bureau of Narcotics and Dangerous Drugs (predecessor to the Drug
Enforcement Administration) considered the idea of HMT to be a "medical
surrender on the treatment of addiction" that would have the effect of
"consigning hundreds of thousands of our citizens to the slavery of heroin
' 85
addiction forever."'
More recently, Congress convened hearings in response to the Swiss
heroin maintenance trials. 186 The hearings called two Swiss doctors as
witnesses, both of whom were strong opponents of both needle exchange
programs and HMT.187 The doctors and two U.S. witnesses condemned

180. Health Consequences of Marijuana Abuse: Recent Findings and the Therapeutic
Uses of Marijuana and the Use of Heroin to Reduce Pain, H.R. Rep. 96-2-5, at 32 (1980);
see also Stoll, supra note 174, at 173.
181.

Stoll, supra note 174, at 179.

182. R. Bayer, Heroin Maintenance:An Historical Perspective on the Exhaustion of
LiberalNarcotics Reform, 8 J.PSYCHEDELIC DRUGS 157-65 (1976).
183.

PETER REUTER

&

ROBERT MACCOUN,

HEROIN

MAINTENANCE:

Is A

U.S.

EXPERIMENT NEEDED? 14, prepared for conference "One Hundred Years of Heroin," Yale

Medical School (September 1998).
184.

Id. at 15.

185.

Id.

186. See generally Needle Exchange Programs: Hearing of the National Security,
InternationalAffairs and CriminalJustice Subcomm. of the H. Government Reform and

Oversight Comm., 105th Cong. (1997).
187.

Reuter & MacCoun, supra note 183, at 16; Needle Exchange Programs:Hearing

of the National Security, InternationalAffairs and Criminal Justice Subcomm. of the H.

Government Reform and Oversight Comm., 105th Cong., 32 (1997) (statements of Ernst
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and the first step
heroin maintenance as "a fast track to moral corruption
' 88
towards genuine disintegration of public security."'
Despite heroin's losing record in Congress, the U.S. experience with
methadone suggests that even the most zealous opposition can be overcome
with enough evidence and support. Although it is now regarded as the most
successful treatment of opioid addiction,' 89 the introduction of methadone as
9
a viable treatment option was initially met with fervent resistance.' 0 In
1973, Congressman Rangel deplored the administration's perceived lack of
effort in combating the American drug addiction problem, and disparaged
the relatively new MMT initiative as a government action "to permanently
narcotize a significant portion of the young and poor."'19 1 In 1998, after two
decades of MMT in the U.S., Senators John McCain (R-AZ), Dan Coats (RIN), and Paul Coverdell (R-GA) submitted a resolution criticizing the use of
methadone to treat heroin, raising concerns that methadone did nothing more
92
than transfer dependence from one highly addictive drug to another. 93
Despite lingering concerns over methadone's addictive qualities,'
methadone
remains the most effective treatment for heroin addiction in the
4
19

U.S.

Aeschbach, Swiss physician and member of board, "Youth Without Drugs" & Erne
Matthias, expert on Swiss drug policy).
188. See Needle Exchange Programs:Hearing of the National Security, International
Affairs and Criminal Justice Subcomm. of the H. Government Reform and Oversight

Comm., 105th Cong., 3 (1997) (statement of Rep. Hastert (R-IL)).
189.

See METHADONE supra note 34; METHADONE MAINTENANCE TREATMENT, supra

note 5, at 1.
190. See 134 Cong. Rec. 25618, 25830-31 (daily ed. Sept. 27, 1988) (statement of
Rep. Rangel).
191.

Id.

192. 144 Cong. Rec. 25061, 25159-60 (daily ed. Oct. 9, 1998) (statements of Sens.
McCain, Coats, & Coverdell).
193.

See 146 Cong. Rec. 19013, 19110-12 (daily ed. Sept. 22, 2000) (statement of

Sen. Levin).
194.

See METHADONE, supra note 34; METHADONE MAINTENANCE TREATMENT, supra

note 5, at 1.
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After years of condemning heroin as a plague and an enemy, it would be
difficult to garner sup ort for prescribing it to heroin addicts in the name of
addiction treatment.
Specifically, it is difficult to imagine either the
Attorney General or the Secretary of Health and Human Services proactively
initiating hearings to amend heroin's placement in the CSA Schedules.
However, similar arguments against methadone eventually ebbed in the face
of compelling evidence of the drug's utility.1 96 The success of the European
and Canadian trials may provide enough evidence to overcome the fierce
opposition that HMT is sure to face.
B. State Legislation: EncouragingStates to Experiment with HAIT
Although the American journey to HMT begins with federal action, it
cannot be limited to federal direction. An HMT program instituted at the
national level would likely be too uniform to account for community
differences, and would impose upon unwilling Americans an addiction
treatment program they may not support or understand. A federallyconstructed HMT program would be an enormous undertaking. Without the
participation of at least a majority of states, it would likely fail in a notorious
and very public way. A program as controversial as HMT should be
instituted by individual, interested populations-such as individual statesthat are willing to support and investigate a program that may be unpopular
with the national majority.
Progressive state legislation in the area of drug control is not a novel
concept. In 1996, Arizona voters passed Proposition 200, also known as the
197
Drug Medicalization, Prevention and Control Act of 1996 (DMPCA).
The proposed legislative amendment would permit CSA Schedule I drugs to
be used for medical purposes. 98 The proposal was an effort to recognize

195.

Reuter & MacCoun, supra note 183, at 17-19.

See id See also METHADONE, supra note 34; METHADONE MAINTENANCE
supra note 5, at 1-2 (stating that MMT is "the most effective treatment for
opiate addiction," despite controversy and criticism "in the U.S. and other countries").
196.

TREATMENT,

197. Dominica Minore Bassett, Comments & Legislative Reviews: Medical Use and
Prescriptionof Schedule I Drugs in Arizona: Is the Battle Moot?, 30 Ariz. St. L.J. 441,
441-42 (1998). See also Louis Sahagun, Arizona Begins Revolt Against Drug War, L.A.
TIMES, Dec 10, 1996, at IA, available at http://articles.latimes.com/1996-1210/news/mn-7548 1 drug-policy.
198. The Drug Medicalization, Prevention, and Control Act of 1996, § 3(2), Ariz.
Prop. 200.
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drug abuse as a public health problem that should be addressed medically
rather than criminally. 199 After several years of legislative modification, the
DMPCA was eventually enacted under Arizona's criminal code, limiting
medical prescription of Schedule I substances "to treat a disease, or to
pain and suffering of a seriously ill patient or terminally ill
relieve the
While fourteen states have enacted legislation legalizing
patient. '200
medicinal use of marijuana,2 ° 1 Arizona is the only state to legalize
prescription of all Schedule I substances.
1. Benefits - "States as Laboratories"
Allowing individual states to experiment with HMT programs in their
own communities, without interference from federal drug control officials,
would provide the rest of the country with concrete evidence to support
establishment of more HMT clinics nationwide. Although the European and
Canadian studies provide substantial evidence, additional support from
successful U.S. HMT programs or studies would afford American people
with evidence that HMT works within the context of the U.S. heroin abuse
problem.
The argument for "states as laboratories" is an established one. In 1932,
Justice Brandeis celebrated the American federal system for the possibility
"that a single courageous State may, if its citizens choose, serve as a
laboratory; and try novel social and economic experiments without risk to
the rest of the country." 20 2 Nearly seventy-five years later, Justice O'Connor
law
reiterated that point in support of the Compassionate Use Act, a state
2 3
0
enacted in 1996 that legalized medical use of marijuana in California.
In a country with a population of over 300 million people, the idea of
governing everyone with one policy is short-sighted. Indeed, one of James

199. The Drug Medicalization, Prevention, and Control Act of 1996, § 2(1), Ariz.
Prop. 200.
200. Ariz. Rev. Stat. § 13-3412.01 (2009); see "Reform in Arizona," DRUG POLICY
http://www.drugpolicy.org/statebystate/arizona/ (last visited Mar.
18, 2010) (describing the struggle between Arizona voters and the legislature in finalizing
terms of DMPCA).
ALLIANCE NETWORK,

201.

See Active State Medical Marijuana Programs, supra note 18.

202. New State Ice Co. v. Liebmann, 285 U.S. 262, 311 (1932) (Brandeis J.,
dissenting).
203.

Gonzales v. Raich, 545 U.S. 1, 42 (2005) (O'Connor J., dissenting).
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Madison's arguments in support of the Constitution was that a large, unified
polity would be made up of so many differing politics and opinions that no
one "faction" (the antithesis to democracy, in Madison's view) could seize
control of the entire nation and enforce a tyranny of the maiority. 204 This
system best supports the ideals of democracy, and satisfies more citizens
than would an all-encompassing unitary power. 0 5 Under federalism, a voter
who is in the political minority of his community has a choice. The voter
can stay and live under a policy with which he does not agree, or "vote with
[his] feet" and move to a community that comports more with his political
views. 206 The "states as laboratories" system supported by federalism is
particularly conducive to the issue of HMT in the U.S. By allowing the
individual states to experiment with HMT, the federal government avoids
the risk of large-scale (and public) failure and simultaneously allows for the
accumulation of U.S. evidence of HMT efficacy.
2. Obstacles- Gonzales v. Raich and its Effect on "States as
Laboratories"
The CSA, particularly after Gonzales v. Raich, which effectively outlaws
inter alia the use of Schedule I substances, preempts any state legislation
legalizing medicinal use of Schedule I substances.
In Raich, the Supreme
Court upheld the jurisdiction of the CSA over the sale, manufacture, and
possession of all drugs in the U.S., whether in intrastate or interstate
commerce. 08 The federally-enacted CSA, and the federal agents acting
under its authority, rely upon Article I, Section 8, Clause 3 of the U.S.
Constitution, the Commerce Clause, for their federal power. 2 0 9 Under U.S.
law, there are three categories of activities that Congress may regulate under

204.

THE FEDERALIST PAPERS

No. 10 (James Madison).

205. See Ilya Somin, Gonzales v. Raich: Federalism as a Casualty of the War on
Drugs, 15 CORNELL J. L. & PUB. POL'Y 507, 540 (2006).
206.

Id.at 541.

207. See U.S. CONST., art. VI, cl. 2. "The Supremacy Clause unambiguously provides
that if there is any conflict between federal and state law, federal law shall prevail."
Raich, 545 U.S. at 29.
208.

Raich, 545 U.S. at 22.

209. Drug Abuse Prevention & Control, 21 U.S.C. § 801(3) (2009). "A major portion
of the traffic in controlled substances flows through interstate and foreign commerce.
Incidents of the traffic which are not an integral part of the interstate or foreign flow ...
nonetheless have a substantial anddirect effect upon interstate commerce." Id.
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its Commerce Clause powers: "channels of interstate commerce ... ,
instrumentalities of interstate commerce, and persons or things in interstate
activities],
commerce [even though the threat may come only from intrastate
210
and activities that substantially affect interstate commerce."
The Raich Court reasoned that Congress could have a rational belief that a
producer of medicinal marijuana whose supply is in excess of his legitimate
customer demands might sell the excess marijuana to someone out of
state. 211 While one instance of such behavior is not significant enough to
affect interstate commerce, an aggregation of many similar instances could
have a significant effect on interstate commerce and the interstate drug
market.2 12 Therefore, Congressional supervision under the CSA is
permissible pursuant to the Commerce Clause. 2 13 Additionally, the Court
recognized that the California Health and Safety Code, which permits
doctors to prescribe marijuana for a patient afflicted with "any other illness
for which marijuana provides relief' is open-ended and "broad enough to
allow even the most scrupulous doctor to conclude that some recreational
uses would be therapeutic." 2 14 In contrast, the use of most prescribed legal
drugs is constrained by "the dosage and duration of the usage. 21 5 The Court
reasoned that the liberal discretion provided to doctors in prescribing
marijuana "provides them with an economic incentive to grant their patients
permission to use the drug." 2 16 The Court determined that the combination
of the economic incentive and the aggregation theory have a substantial
relation to or effect on interstate commerce and justify Congress's regulation
217
of noncommercial drug-related activities.

210. See Raich, 545 U.S. at 16-17; U.S. v. Lopez, 514 U.S. 549, 558-59 (1995); U.S.
v. Morrison, 529 U.S. 598, 608-09 (2000).
211.

Raich, 545 U.S. at 30-32.

212.

Id. at 32.

213.

Id at 32-33.

214.

Id. at 31.

215.

Id. at

216.

Id.

217.

Raich, 545 U.S. at 30-33.

30.
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2 19
18
Raich was decided after U.S. v. Lopez2 in 1995 and U.S. v. Morrison
in 2000, and was a surprising departure from the Commerce Clause
interpretation in those cases. Both cases involved challenges to federal
legislation that would have authorized strict regulations, based upon
Congress' Commerce Clause powers. 220 Neither case found the regulated
activity-gun-possession in Lopez, and violent crime in Morrison-to be
permissibly regulated under the Commerce Clause. 22 The Court expressed
concern in both cases that by allowing Congress to regulate the activity at
issue, it would give Congress limitless control over 222
areas of individual
action that were traditionally left to the states to regulate.
The rationale behind the Raich decision is strikingly similar to the
government's arguments in Lopez and Morrison-relation to interstate

218.

See generallyU.S. v. Lopez, 514 U.S. 549 (1995).

219.

See generally U.S. v. Morrison, 529 U.S. 598 (2000).

220. In Lopez, the Court ruled that the Gun-Free School Zones Act of 1990, which
prohibited possession of a firearm in a school zone exceeded Congress' authority to
regulate under the Commerce Clause. See generally Lopez, 514 U.S. at 549. In
Morrison, the Court ruled that the Violence Against Women Act, providing a federal
civil remedy for victims of gender-motivated crimes, was a similarly unconstitutional
extension of Congress' Commerce Clause powers. See generally Morrison, 529 U.S. at
598.
221.

Morrison,529 U.S. at 615-16; Lopez, 529 U.S. at 564.

222. The Court noted:
If accepted, petitioners' reasoning would allow Congress to regulate any crime
as long as the nationwide, aggregated impact of that crime has substantial
effects on employment, production, transit, or consumption... [and] will not
limit Congress to regulating violence but may, as we suggested in Lopez, be
applied equally as well to family law and other areas of traditional state
regulation since the aggregate effect of marriage, divorce, and childrearing on
the national economy is undoubtedly significant.
Morrison, 529 U.S. at 615-16.
Under the theories that the Government presents in support of § 922(q), it is
difficult to perceive any limitation on federal power, even in areas such as
criminal law enforcement or education where States historically have been
sovereign. Thus, if we were to accept the Government's arguments, we are
hard pressed to posit any activity by an individual that Congress is without
power to regulate.
U.S. v. Lopez, 514 U.S. 549, 564 (2005).

The Journalof ContemporaryHealth Law and Policy Vol. XXVI:2

commerce and aggregation of activities-and yet, the Court came to the
opposite conclusion in Raich.223 The Raich Court distinguished the case
from Lopez and Morrison by drawing a distinction between the respondents'
arguments in both cases. 224 According to the Court, the respondents in
Raich challenged the constitutionality of "individual applications of a
concededly valid statutory scheme [the CSA]" whereas Lopez and Morrison
225
challenged the constitutionality of the statutory schemes themselves.
Whether or not such a distinction is valid, the result has been the vast
expansion of federal control over individual actions and severe
encroachment upon traditional areas of state sovereignty-the very concerns
behind the decisions of Lopez and Morrison.
Chief Justice Rehnquist and Justices O'Connor and Thomas dissented,
rejecting the Court's acceptance of a tenuous connection between intrastate
marijuana production and consumption and interstate commerce. 226 Justice
O'Connor expounded on Justice Brandeis' 1932 concept of states as
laboratories for democracy, describing the extensive jurisdiction of the CSA
as "stifl[ing] an express choice by some States, concerned for the lives and
liberties of their people, to regulate [drugs] differently." 227 She insisted that
federal law must protect the space states have to experiment. 228 The views
of these credible and distinguished jurists could someday be the basis for
revisiting the Raich decision and its expansion of the CSA.
Since Raich, the CSA enjoys nearly unbridled jurisdiction over drug
offenses anywhere in the U.S. This renders progressive legislation, like
Arizona's DMPCA, impotent. 229 With federal law occupying the traditional
state fields of criminal law and public health, states are unwilling or unable
230
to experiment with innovative and modem solutions for old problems.

223.

Gonzales v. Raich, 545 U.S. 1, 33 (2005).

224.

See discussion at Sec. IV; Raich, 545 U.S. at 23.

225.

Raich, 545 U.S. at 23.

226.

Id. at 42 (O'Connor J., dissenting).

227.

Id. at 57 (O'Connor J., dissenting).

228.

Id.

229. See Kiefer, supra note 20; Stern & DiFonzo, supra note 20, at 720 n. 340; Boyd,
supra note 20, at 1260.
230.

See Kiefer, supra note 20.
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The stifling effects of Raich on state autonomy and federalism can be
compared to the similar effects that resulted from Prohibition Era
legislation. 231 Like the CSA, the Eighteenth Amendment and subsequent
Prohibition legislation grossly increased the federal government's oversight
of criminal law. 232 This resulted in an increase in the federal prison
population by more than fifty percent. 233 Similarly, post-CSA America saw
an increase in incarcerated drug offenders from 16.3 percent of the
incarcerated population in 1970 to 61.3 percent in 1994. 3 After Raich, that
percentage decreased to fifty-three percent by 2006,235 still more than three
times the proportion in 1970.
The Eighteenth Amendment and its progeny also served to severely thwart
U.S. federalism and the opportunity for U.S. citizens to seek out
communities with political opinions similar to their own. 23 6 Instead,
residents of "Wet" states were forced to conform to a national standard that
they did not support. 237 Under the CSA, modem citizens are likewise
deprived of the opportunity to participate effectively in their own
governance. 238 While some dissent is inevitable with the passage of any

231. It is particularly notable that Prohibition Era legislation began with the
Eighteenth Amendment, a constitutional amendment that implies that the broad
congressional powers over alcohol control could not have been supported by the
Commerce Clause, as Congress and the Court reasoned with the CSA. See Somin, supra
note 205, at 547-50.
232.

Id. at 548.

233. Federal prison population increased from 5000 in 1920 to 12,000 in 1930. See
Richard F. Hamm, SHAPING THE 1 8 TH AMENDMENT: TEMPERANCE, LEGAL CULTURE, AND
THE POLITY, 1880-1920 267 (University of North Carolina Press 1995).
234.

BUREAU OF JUSTICE STATISTICS SOURCEBOOK OF CRIMINAL JUSTICE STATISTICS

2003 519 t. 6.57 (2004).
235.

WILLIAM

J.

SOBEL

ET

AL.

PRISONERS

IN 2006

Table

12

(2006),

http://proxy.baremetal.com/csdp.org/research/p06.pdf (indicating that 93,751 of the total
federal prision population of 176,268 inmates were drug offenders).
236.

See discussion at Sec. IV, Somin, supra note 205, at 547.

237.

Somin, supra note 205, at 548.

238. Fourteen U.S. states have enacted legislation legalizing medical use of
marijuana. See Active State Medical Marijuana Programs, supra note 18.
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legislation, Congress should not be allowed or even inclined to marginalize a
vast proportion of the population 239 by usurping state autonomy.
State legislation establishing an HMT program could easily address the
problems posed by the Raich Court. The Court's concern with a patient's
sale of any excess of his prescription heroin is negated by the design of the
HMT procedure because, in the majority of HMT programs, patients receive
their heroin doses in a clinic and are not permitted to remove any heroin
from the premises. 240 Rather, patients self-administer their heroin dosage in
the clinic, and are subsequently monitored for a period of time (usually thirty
minutes). 24 1 The post-administration supervision not only protects against
complications and overdoses, but also ensures that patients do not sneak
extra heroin out with them when they leave the clinic.
The one caveat that HMT clinics may face is that they must obtain a
stock of heroin from somewhere. If a clinic's supply came from out-ofstate, the transaction would undeniably put HMT clinics within the
jurisdiction of the CSA. However, if the federal government amends the
CSA to re-categorize heroin from Schedule I to Schedule II and establishes
regulations for HMT clinics generally, then the CSA would no longer pose a
threat to HMT programs or the state communities that would launch them.
Thus, HMT depends not only upon the re-categorization of heroin as a
dangerous, yet medically-valuable, substance, but also upon federal restraint
under the CSA.
C. The Obama Administration and Hopefor Change in Drug Control
The tide of U.S. drug policy may be shifting in favor of state autonomy
under the Obama Administration. In October 2009, the U.S. Department of
Justice issued a memorandum discouraging federal prosecutors from

239.

In 1915, four states--California, Texas, Missouri, and Pennsylvania-had

rejected Prohibition, and sixteen-Ohio, Nebraska, Indiana, Michigan, Massachusetts,
Connecticut, South Dakota, Iowa, Illinois, Alabama, Maryland, New York, Vermont,
Rhode Island, New Hampshire, and Delaware-had tried Prohibition and rejected it. See
Liquor Men's Sweeping Claims: They Maintain That There Is More Poverty, Insanity and
Crime, and Fewer Church Members, in 'Dry' States, N. Y. TIMES, March 14, 1915, at

SM20, available at http://query.nytimes.com/gst/abstract.html?res=9BO6EEDFl03D
E333A25757CIA9659C946496D6CF. Today, fifteen states have enacted legislation that
controverts the CSA. See Active State Medical Marijuana Programs, supra note 18; ARIZ.
REv. STAT. § 13-3412.01 (2009).
240.

Perneger et al., supra note 11, at 14; Haasen et al., supra note 11, at 56.

241.

Perneger et al., supra note 11, at 14; van den Brink et al., supra note 11, at 310.
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targeting medicinal marijuana users and their suppliers. 242
The
memorandum advised that it is not a good use of resources to prosecute
"individuals whose actions are in clear and unambiguous compliance with
existing state laws providing for the medical use of marijuana. ' 243 The
Obama Administration's recognition of the states' autonomy in passingand now enforcing-legislation legalizing medicinal marijuana use signals a
significant move away from the more stringent drug policies of past
administrations. 244 If this recognition of states' rights extends to Arizona's
DMPCA, then Arizona's implementation of an HMT study could be
facilitated.24 5
Scientific research on Schedule I substances has progressed under the
radar of the legislative struggle. In September 2008, the FDA approved
research on the effect of lysergic acid diethylamide, or LSD, on "end-of-life
anxiety in terminally ill patients." 246 Though the study was conducted in
Switzerland, the FDA's approval allows data from the clinical trials to be
used in the U.S. 247 In 2004, a researcher in South Carolina obtained FDA
approval to study the therapeutic effects of MDMA, more commonly known

242. Memorandum from Justice Dep't on Investigations and Prosecutions in States
Authorizing the Medical Use of Marijuana to Selected United States Attorneys (Oct. 19,
2009)
[hereinafter
Memorandum
from
Justice
Dep't],
available at
http://blogs.usdoj.gov/blog/archives/192; See also Maryuana Policy Is Shifted,
WASHINGTON POST EXPRESS, Oct. 20, 2009 at 5 [hereinafter Mar 'uana Policy Is Shifted].
243. Memorandum from Justice Dep't, supra note 242; See also MariJuanaPolicy Is
Shifted, supra note 242.
244.

See MarjuanaPolicy Is Shifted, supra note 242.

245. Memorandum from Justice Dep't, supra note 242. Since the memorandum
specifies "compliance with existing state laws", it is likely that only Arizona, protected
by its DMPCA, could possibly establish an HMT program before any federal drug law
changes occur. Id. (emphasis added).
246. Carolyn Gregoire, The Psychotherapy Movement: Acid's Long Trip Back to
Clinical Research, MCGILL
TRIB., Sept. 29, 2009, at 10-11, available at

http://media.www.mcgilltribune.com/media/storage/paper234/news/2009/09/29/Features/
The-Psychotherapy.Movement.Acids.Long.Trip.Back.To.Clinical.Research3786192.shtml.
247.

Id.

338
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as ecstasy, on symptoms of post-traumatic stress disorder. 248 Since both
LSD and MDMA are categorized as Schedule I substances, a compelling
case can be made that these studies set a precedent for studies
of the
249
medicinal value of other Schedule I substances, such as heroin.
Opponents may point out that LSD and MDMA are hallucinogens,
whereas heroin is a narcotic. The important difference between these classes
of illicit drugs is that hallucinogens are generally not physically addictive,
whereas heroin, a narcotic, is physically addictive. 250 The non-addictive
nature of hallucinogens like LSD and MDMA, some might argue, make
them less dangerous for use in therapy. However, hallucinogens are
psychologically addictive: they cause a psychological reaction-feelings of
euphoria or dramatic hallucinations-that users then seek to experience
repeatedly until they become psychologically dependent on the drug. 25 1 This
psychologically addictive potential is likely what earned LSD and252
MDMA
their places in Schedule I, alongside the physically addictive heroin.
Even if one were to argue that the supervised administration of LSD and
MDMA in these studies off-set the danger of addiction, this argument fails

248. See NIH, A TEST OF MDMA-AsSSITED PSYCHOTHERAPY IN PEOPLE WITH
POSITRAUMATIC
STRESS
DISORDER
(2004),
http://clinicaltrials.gov/ct2/show/

NCT00090064. The ongoing study is currently in its second phase. Id.
249. Approval was likely possible because of the Raich Court's interpretation of the
CSA to "prohibit entirely the possession or use of substances listed in Schedule I, except
as a part of a strictly controlled research project." Gonzales v. Raich, 545 U.S. 1, 24
(2005) (emphasis added).
250.

(2009),

NIDA INFOFACTS, HALLUCINOGENS: LSD, PEYOTE, PSILOCYBIN, AND PCP 3

http://www.drugabuse.gov/pdf/infofacts/Hallucinogens09.pdf

[hereinafter

HALLUCINOGENS: LSD, PEYOTE, PSILOCYBIN, AND PCP]; NIDA InfoFacts, MDMA
("ECSTASY")
2
(2010)
[hereinafter
MDMA
("ECSTASY")],

http://www.drugabuse.gov/PDF/Infofacts/MDMA 10.pdf.
251.

HALLUCINOGENS: LSD, PEYOTE, PSILOCYBIN, AND PCP, supra note 250, at 3;

MDMA ("ECSTASY"), supra note 250, at 2.
252. See Drug Abuse Prevention & Control, Schedule I(a)(9), Schedule l(b)(10), &
Schedule I(c)(l) (2009). Indeed, the U.S. Drug Enforcement Administration equates
LSD with MDMA and heroin when describing LSD's scheduling in the Controlled
Substances Act. DEA, LSD, http://www.justice.gov/dea/concernlsd.html#foot3 (last
visited Mar. 18, 2010). "LSD is a Schedule I substance under the Controlled Substances
Act. Schedule I drugs, which include heroin and MDMA, have a high potential for abuse
and serve no legitimate medical purpose." (emphasis added). Id.
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considering that HMT features similarly supervised administration and
would be designed to avoid exacerbating the addiction problem. Another
likely argument is that the LSD and MDMA studies test the medicinal value
of these substances in treating unrelated psychological disorders, whereas
HMT is a process of treating heroin addiction with heroin. However, this
argument raises the question of how logical it would be to expose
participants, already suffering from psychological distress, to the potentially
addictive nature of Schedule I substances. HMT has been recognized not as
a cure, but as a tool 253 in the addict's gradual progression from addiction to
recovery.
D. The Key to HMT in the UnitedStates

It would be naive to expect the U.S. to establish HMT clinics, which
would legally administer pure, intravenous heroin to heroin addicts, without
extreme caution and oversight. For this reason, the steps to be taken toward
U.S. HMT clinics should be small and heavily regulated. The first step
would be to initiate a study of HMT effectiveness in the U.S. heroinaddicted population. To effectuate a U.S. study of HMT, legislative changes
would need to take place at both the federal and state levels.
At the federal level, the Attorney General or Secretary of Health and
Human Services would need to initiate hearings to re-categorize heroin as a
Schedule II substance. 254 While the Attorney General can initiate these
hearings on his own, the public need not wait for him to do so: the Attorney
255
General can also initiate hearings on the "petition of any interested party."
Moving heroin to Schedule II would illustrate that the government
recognizes the medical value of heroin in an HMT setting, but still considers
it to be an extremely addictive and dangerous substance that requires strict
256
this way. 257
Despite the
Methadone
currently
recognized
regulation.
258 U.S. authorities
can legitimately
heroin as anis illegal
drug,
demonization of

253. Perneger et al., supra note 11, at 13-14, van den Brink et al., supra note 11, at
311; Haasen et al., supra note 11, at 56; March et al, supra note 11, at 204-05; OviedoJoekes et al, supra note 13, at 777.
254.

Drug Abuse Prevention & Control, 21 U.S.C. § 811(b) (2009).

255.

Id.at § 81 l(a).

256.

See Drug Abuse Prevention & Control, 21 U.S.C. § 812(b)(2) (2009).

257.

See id at Schedule 1I(b)(11).

258.

See supra Section IV(A)(b).
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and justifiably rely on the HMT trials in Europe and Canada for evidence of
the successful use of heroin in HMT. Indeed, this possibility was left open
in the CSA-expanding majority decision of Raich: "[a]s the Solicitor
General confirmed during oral argument, the
259 statute authorizes procedures
for the reclassification of Schedule I drugs."
Once heroin is moved to Schedule II, the U.S. government could
automatically apply the new methadone regulations to the clinical use of
heroin. 260 By subjecting heroin to the same stringent regulations that are
currently applied to methadone, government authorities would not only be
equating heroin with methadone, but would also be secure that the minor
easing of prohibition on heroin would be just that - minor. Heroin would
still be heavily regulated, and would be available only for HMT research and
treatment.
By authorizing heroin for the same usages as methadone, individual states
could start their own HMT clinics-or, more realistically, researchers in
U.S. institutions could conduct U.S. studies on HMT effectiveness. Indeed,
for the purposes of an HMT study, the federal government need not initiate
lengthy and arduous rescheduling hearings. The Raich court interpreted the
CSA to "prohibit entirely the possession or use of substances listed 26in1
Schedule I, except as a part of a strictly controlled research project.,
Once a study of HMT effectiveness has been conducted and replicated in the
U.S., American legislators and the American public may become more
confident in the value of and need for HMT. By the same token, HMT
clinics would not be imposed upon unwilling states by a federal system.
Instead, states with more aggravated heroin problems and a genuine interest
in HMT could establish clinics within their states, largely on their own
terms. Although evidence suggests that HMT clinics do not cause any
disturbance to surrounding neighborhoods, 262 citizens who oppose the
introduction of HMT clinics could "vote with their feet,, 263 and move to an
HMT-free community.
While the decision in Raich appears problematic, it merely upheld the
application of the CSA, specifically the actions of federal agents who seized

259.

Gonzales v. Raich, 545 U.S. 1, 33 (2005).

260.

See supra Section

261.

Raich, 545 U.S. at 24 (emphasis added).

262.

See Pemeger et al., supra note 11, at 17.

263.

Somin, supra note 205, at 541.
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264
and destroyed a substance that is listed as a prohibited Schedule I drug.
The concerns regarding federal preemption of state drug laws after Raich is
only realized if federal agents act on their authority under the CSA. Under
the Obama administration, federal prosecutors have been instructed to avoid
prosecuting medical marijuana patients and their suppliers if those
individuals' actions were in accordance with an existing state law permitting
medicinal use of marijuana. 265 If a similar direction were given for heroin
obtained for HMT studies, researchers would have nothing to fear from the
expanded post-Raich CSA, assuming that the researcher in possession of
heroin was operating legally under applicable regulations.
Any U.S. initiative toward studying HMT will likely face significant
opposition, but such resistance will probably focus on political and moral
opinions. Practically, it is possible to begin an HMT study in the U.S.
There is abundant scientific evidence to support such a program, 266 and
procedures are built into the CSA to facilitate a substance's scheduling to be
amended, as would be required by an HMT program in the U.S. 267 Perhaps
the Obama Administration's progressive attitude toward drug control 268 will
encourage the changes and initiatives necessary to study the effectiveness of
HMT in the U.S., thereby making treatment available to a previously
unreachable group of heroin addiction sufferers.

264.

Raich, 545 U.S. at 26-27. The court noted:

We have no difficulty concluding that Congress acted rationally in determining
that none of the characteristics making up the purported class, whether viewed
individually or in the aggregate, compelled an exemption from the CSA; rather,

the subdivided class of activities defined by the Court of Appeals was an
essential part of the larger regulatory scheme.
Id.

265. See Memorandum from Justice Dep't on Investigations and Prosecutions in
States Authorizing the Medical Use of Marijuana to Selected United States Attorneys,
supra note 242.
266. See generally Christian Haasen et al., supra note 11; van den Brink et al., supra
note 11; Pemeger et al., supra note 11; Oviedo-Joekes et al., supra note 13.
267.

Drug Abuse Prevention & Control, 21 U.S.C. §§ 811 (b)-(c) (2009).

268.

See supra Subsection D.
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VI. CONCLUSION

The goal of drug control is to eradicate illegal drug use entirely. The
reality, however, is that a considerable number of Americans are already
addicted to dangerous illegal drugs, such as heroin. This state of affairs
must be attacked with the most effective treatment available. While MMT
in the U.S. is effective, it fails to reach a substantial number of suffering
addicts,269 and therefore needs supplementation. The U.S. is faced with
growing evidence that HMT is successful and
safe.27 ° Yet, the current drug
271
control laws fail to recognize these findings.
The CSA should be amended to re-categorize heroin as a Schedule 272
II
drug, recognizing its medical value under "severe restrictions."
Additionally, enforcement of the CSA should be properly limited to
interstate drug problems, such as trafficking, to encourage individual states
to conduct their own studies, "without risk to the rest of the country. ' 273 The
Obama Administration has taken positive steps toward restraining its
enforcement of federal drug laws,274 and several studies of medicinal use of
Schedule I drugs have already been approved by the FDA. 275 These steps
may set the proper precedent for advocating a U.S. HMT study. This would
ensure that thousands of heroin addicts would gain an opportunity for
successful addiction treatment, and U.S. drug policy would take a positive
step toward eliminating heroin addiction.

269.

METHADONE,

supra note 34.
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